Cure8 research brief
If the colonic epithelium can retain a molecular "memory" of prior inflammation, that may help explain relapses after apparent remission and could point to new biomarkers or therapies aimed at restoring healthy epithelial function rather than only suppressing inflammation.
Researchers, translational scientists, and clinicians focused on UC pathogenesis, mucosal healing, or biomarker/assay development.
This review summarizes evidence that colonic epithelial cells in ulcerative colitis can retain an "inflammatory memory"—molecular and chromatin changes that persist after inflammation resolves and that may alter how the epithelium responds to subsequent injury or repair.
The authors draw on patient-derived colonic organoid studies and lineage-resolved colitis models showing persistent changes in enhancer accessibility and other molecular layers (histone marks, DNA methylation, metabolism), while noting that baseline inflammatory gene expression can normalize during organoid expansion.
The review distinguishes persistent epithelial states from ongoing niche stimulation, reversible adaptation, fixed injury, and clonal selection, and highlights translational opportunities such as biopsy-linked organoid recall assays and longitudinal sampling.
It also states that no validated epithelial memory assay or memory-directed therapy is yet ready for routine clinical care.
This is a review article (Frontiers in Immunology) summarizing experimental and translational evidence; it does not present a validated clinical test or approved therapy. Heterogeneity across patients and regions and the need for stepwise assay validation are emphasized.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A reusable transcriptomic atlas could let researchers compare new IBD biopsy datasets to a common reference, improving cross-study comparisons and helping separate inflammation from persistent disease-state biology that...
This research links higher GOLM1 levels in UC patients to impaired intestinal barrier function through EGFR–p38 MAPK signaling, a pathway relevant to inflammation and permeability. If validated, GOLM1 could become a...
If validated, mucosal biomarkers like SPARC and SPP1 might help predict who will not respond to infliximab, potentially guiding treatment choices and avoiding ineffective therapy for some people with UC.
